Macimorelin
From Infogalactic: the planetary knowledge core
Names | |
---|---|
IUPAC name
2-Amino-N-[(2R)-1-[[(1R)-1-formamido-2-(1H-indol-3-yl)ethyl]amino]-3-1H-indol-3-yl)-1-oxopropan-2-yl]-2-methylpropanamide
|
|
Other names
Aib-Trp-gTrp-CHO; AEZS-130; JMV 1843; Macimorelin acetate
|
|
Identifiers | |
381231-18-1 945212-59-9 (acetate) |
|
ChemSpider | 7980698 |
Jmol 3D model | Interactive image |
PubChem | 9804938 |
|
|
|
|
Properties | |
C26H30N6O3 | |
Molar mass | 474.57 g·mol−1 |
Pharmacology | |
ATC code | V04 |
Vapor pressure | {{{value}}} |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
|
|
Infobox references | |
Macimorelin (INN) is a drug being developed by Æterna Zentaris for use in the diagnosis of adult growth hormone deficiency. As of January 2014, it is in Phase III clinical trials.[1]
Macimorelin is a mimic of ghrelin, a growth hormone secretagogue. It binds to the growth hormone secretagogue receptor (GHSR) causing release of growth hormone from the pituitary gland.[2][3][4]
See also
- Anamorelin
- Capromorelin
- Examorelin (hexarelin)
- GHRP-6 (SKF-110679)
- Ibutamoren (MK-677)
- Ipamorelin
- Pralmorelin (GHRP-2)
- Relamorelin
- SM-130,686
- Tabimorelin
References
<templatestyles src="Asbox/styles.css"></templatestyles>
Categories:
- Chemical articles with multiple CAS Registry Numbers
- Articles without EBI source
- Articles without KEGG source
- Articles without UNII source
- Pages using collapsible list with both background and text-align in titlestyle
- Articles containing unverified chemical infoboxes
- Ghrelin receptor agonists
- Growth hormone secretagogues
- Hormonal agents
- Indoles
- Peptides
- Formamides
- Systemic hormonal preparation stubs